ARS Pharmaceuticals (SPRY) EBT (2020 - 2026)
ARS Pharmaceuticals recorded quarterly EBT of -$62.6 million in Q1 2026, down 161.36% quarter-over-quarter from $102.0 million in Q4 2025, and down 68.35% year-over-year from -$197.7 million in Q1 2025.
ARS Pharmaceuticals' EBT history runs 7 years deep, the most recent figure standing at -$62.6 million for Q1 2026.
- In Q1 2026, EBT fell 68.35% year-over-year to -$62.6 million; the TTM figure through Mar 2026 stood at -$61.4 million (down 126.83% YoY), while the FY2025 annual figure was -$171.4 million, down 2169.53% from the prior year.
- EBT came in at -$62.6 million for Q1 2026 at ARS Pharmaceuticals, down from $102.0 million in the prior quarter.
- In the past five years, EBT ranged from a high of $102.0 million in Q4 2025 to a low of -$62.6 million in Q1 2026.
- A 5-year average of -$8.7 million and a median of -$15.4 million in 2022 frame the typical range for EBT.
- On a YoY basis, EBT climbed as much as 397.08% in 2023 and fell as far as 224.76% in 2023.
- ARS Pharmaceuticals' EBT stood at -$15.4 million in 2022, then surged by 397.08% to $45.9 million in 2023, then grew by 2.88% to $47.2 million in 2024, then surged by 116.1% to $102.0 million in 2025, then sank by 161.36% to -$62.6 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$62.6 million, $102.0 million, and -$53.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 221.65 Mn |
| 10 | ARS Pharmaceuticals | 900.62 Mn | 699.65 Mn | - | -62.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.59 Mn |
| Dec 31, 2025 | 101.99 Mn |
| Sep 30, 2025 | -53.19 Mn |
| Jun 30, 2025 | -47.61 Mn |
| Mar 31, 2025 | -37.18 Mn |
| Dec 31, 2024 | 52.02 Mn |
| Sep 30, 2024 | -21.75 Mn |
| Jun 30, 2024 | -15.34 Mn |
| Mar 31, 2024 | -13.19 Mn |
| Dec 31, 2023 | 45.88 Mn |
| Sep 30, 2023 | -17.98 Mn |
| Jun 30, 2023 | -20.60 Mn |
| Mar 31, 2023 | -18.71 Mn |
| Dec 31, 2022 | -15.44 Mn |
| Sep 30, 2022 | -6.63 Mn |
| Jun 30, 2022 | -6.34 Mn |
| Mar 31, 2022 | -7.10 Mn |
| Dec 31, 2021 | 46.62 Mn |
| Sep 30, 2021 | -22.68 Mn |
| Jun 30, 2021 | -24.51 Mn |
| Mar 31, 2021 | -18.89 Mn |
| Dec 31, 2020 | -13.10 Mn |
| Sep 30, 2020 | -8.11 Mn |
| Jun 30, 2020 | -6.46 Mn |
| Mar 31, 2020 | -5.24 Mn |